News & Updates

Show Multimedia Only

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026 by

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

16 Apr 2026 by

Silymarin therapy combined with lifestyle interventions can reduce and normalize liver enzyme levels in patients with nonalcoholic fatty liver disease (NAFLD) and associated metabolic syndrome (MetS), a recent study has shown.

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

16 Apr 2026

Testosterone therapy helps alleviate menopause symptoms in breast cancer survivors

16 Apr 2026

In perimenopausal and postmenopausal women with a history of breast cancer, testosterone therapy appears to yield substantial improvements in menopause symptoms, as shown in a small retrospective study.

Testosterone therapy helps alleviate menopause symptoms in breast cancer survivors

16 Apr 2026

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

15 Apr 2026

In individuals at risk of rheumatoid arthritis (RA), 12 months of treatment with hydroxychloroquine falls short of preventing the development of the disease, according to the results of a phase II trial.

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

15 Apr 2026

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026 by

Gotistobart monotherapy elicits an improved and durable antitumour response with a meaningful survival benefit relative to docetaxel in patients with metastatic squamous nonsmall cell lung cancer (sqNSCLC) who experience disease progression on or after anti-PD-(L)1 treatment, as shown by the results of the stage 1 PRESERVE-003 phase III trial.

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026

GERD worsens cough in fibrotic interstitial lung disease

15 Apr 2026

In patients with fibrotic interstitial lung disease (ILD), the severity of cough appears to be worse in the presence of gastroesophageal reflux disease (GERD), according to a retrospective study.

GERD worsens cough in fibrotic interstitial lung disease

15 Apr 2026

Mavacamten reduces blood flow obstruction in adolescents with HCM

14 Apr 2026 by

Treatment with mavacamten, compared with placebo, results in significantly greater reduction in left ventricular outflow tract (LVOT) obstruction over 28 weeks among adolescent patients with obstructive hypertrophic cardiomyopathy (HCM), as shown in the SCOUT-HCM trial.

Mavacamten reduces blood flow obstruction in adolescents with HCM

14 Apr 2026

ILD ups risks of pneumonitis, mortality in patients taking ICIs

14 Apr 2026

Among patients receiving immune checkpoint inhibitors (ICIs), those with interstitial lung disease (ILD) have a significantly greater risk of developing checkpoint inhibitor pneumonitis (CIP) and may experience worse outcomes, including recurrence and death, reveals a study.

ILD ups risks of pneumonitis, mortality in patients taking ICIs

14 Apr 2026

Adjunctive soticlestat minimally beneficial in Lennox–Gastaut syndrome

14 Apr 2026

Use of the cholesterol 24-hydroxylase inhibitor soticlestat as adjunctive therapy in patients with Lennox–Gastaut syndrome (LGS) falls short of reducing the frequency of major motor drop (MMD) seizures, according to the results of the phase III SKYWAY trial.

Adjunctive soticlestat minimally beneficial in Lennox–Gastaut syndrome

14 Apr 2026

Real-world evidence positions nirsevimab ahead in infant RSV prevention

14 Apr 2026

Respiratory syncytial virus (RSV) remains a leading cause of hospitalisation and severe lower respiratory tract infection (LRTI) in infants worldwide. [Lancet 2022;399:2047-2064; Lancet 2017;390:946-958] In recent years, two immunoprophylactic strategies have become available to protect infants, namely maternal immunisation with the RSV prefusion F (RSVpreF) vaccine and passive immunisation of infants with the long-acting monoclonal antibody nirsevimab.

Real-world evidence positions nirsevimab ahead in infant RSV prevention

14 Apr 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS

Testosterone therapy helps alleviate menopause symptoms in breast cancer survivors

Testosterone therapy helps alleviate menopause symptoms in breast cancer survivors

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

Hydroxychloroquine treatment does not prevent RA onset in at-risk individuals

Gotistobart a chemo-free option for metastatic sqNSCLC

Gotistobart a chemo-free option for metastatic sqNSCLC

GERD worsens cough in fibrotic interstitial lung disease

GERD worsens cough in fibrotic interstitial lung disease

Mavacamten reduces blood flow obstruction in adolescents with HCM

Mavacamten reduces blood flow obstruction in adolescents with HCM

ILD ups risks of pneumonitis, mortality in patients taking ICIs

ILD ups risks of pneumonitis, mortality in patients taking ICIs

Adjunctive soticlestat minimally beneficial in Lennox–Gastaut syndrome

Adjunctive soticlestat minimally beneficial in Lennox–Gastaut syndrome

Real-world evidence positions nirsevimab ahead in infant RSV prevention

Real-world evidence positions nirsevimab ahead in infant RSV prevention